CSL acknowledges shareholder frustration after $3.7B loss

• CSL chairman Brian McNamee acknowledged investor frustration following a period of poor financial performance and executive changes.
• CSL shares have rallied almost 90% since June despite the biotech company reporting a near-$3.7 billion annual loss.
• Management is taking urgent action to reduce fixed costs and address underperforming investments to regain market confidence.

Biotechnology giant CSL (ASX:CSL) has acknowledged shareholder frustration after a tumultuous year marked by executive changes and a near-$3.7 billion annual loss.

The massive statutory loss was driven by significant restructuring costs, leadership transitions, and substantial non-cash balance sheet impairments.

"The past year has been one of significant change for CSL, and the board acknowledges that many shareholders are frustrated with the recent disappointing commercial and financial performance of the company," said CSL Chairman Brian McNamee.

The company admitted that it built up excessive fixed costs, reacted slowly to market competition, and suffered from underperforming research and development investments.

Management is now acting with urgency to rebuild shareholder confidence by improving operational execution and streamlining the business.

Following the announcement, the CSL share price was up at $174.65.

The company previously removed CEO Paul McKenzie after performance fell short of board expectations.